The Europe Transcriptomics Market is expected to witness market growth of 7.1% CAGR during the forecast period (2021 2027).
The transcriptomics market is predicted to grow due to developments in the domain of transcriptomics, such as the widespread use of RNA-sequencing and an increase in applications of transcriptomics, such as drug discovery. Moreover, an increase in financing and grants from various business and government entities is expected to help the market in the long run. In addition, prominent market players are concentrating their efforts on increasing their transcriptomics footprints by strategic alliances and collaborations with other players. Furthermore, the organizations are developing ways to extend their global consumer base. Dovetail Genomics, for example, announced the global availability of its Dovetail HiChIP and Micro-C Kits in February 2020.
In the recent years, due to the genome projects, an increase in R&D expenditure is being undertaken all over the world. The GENE Consortium, a top whole genome sequencing program in Europe, was founded in the United Kingdom with the goal of sequencing up to 100,000 genomes from cancer patients, rare illness patients, and their relatives from 11 genomic medicine institutes. In addition, the Italian Institute of Technology and the European Molecular Biology Laboratory inked a partnership agreement in April 2021 to increase their research collaboration. This agreement is expected to boost their database and allow them to exchange study resources. The RNA program, which focuses on non-coding RNAs, was recently launched at the Italian Institute of Technology.
The high demand to study on Gene Expression Level through Transcriptomics is expected to help the regional market to offer enough opportunities for the industry players. Low-abundance targets and tiny changes in gene expression, which are crucial for investigating the biological response to stimulation or environmental changes, are difficult to detect with gene microarray methods.
The Germany market dominated the Europe Transcriptomics Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $601.4 million by 2027. The UK market is poised to grow at a CAGR of 6.3% during (2021 - 2027). Additionally, The France market is expected to experience a CAGR of 7.9% during (2021 - 2027).
Based on Technology, the market is segmented into q PCR, Microarrays, and Sequencing Technology. Based on Application, the market is segmented into Drug Discovery, Diagnostics & Disease Profiling, and Others. Based on Component, the market is segmented into Consumables, Instruments, Software, and Services. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Fluidigm Corporation, Promega Corporation, General Electric (GE) Co., Merck & Co., Inc., Thermo Fisher Scientific, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., and Qiagen N.V.
The transcriptomics market is predicted to grow due to developments in the domain of transcriptomics, such as the widespread use of RNA-sequencing and an increase in applications of transcriptomics, such as drug discovery. Moreover, an increase in financing and grants from various business and government entities is expected to help the market in the long run. In addition, prominent market players are concentrating their efforts on increasing their transcriptomics footprints by strategic alliances and collaborations with other players. Furthermore, the organizations are developing ways to extend their global consumer base. Dovetail Genomics, for example, announced the global availability of its Dovetail HiChIP and Micro-C Kits in February 2020.
In the recent years, due to the genome projects, an increase in R&D expenditure is being undertaken all over the world. The GENE Consortium, a top whole genome sequencing program in Europe, was founded in the United Kingdom with the goal of sequencing up to 100,000 genomes from cancer patients, rare illness patients, and their relatives from 11 genomic medicine institutes. In addition, the Italian Institute of Technology and the European Molecular Biology Laboratory inked a partnership agreement in April 2021 to increase their research collaboration. This agreement is expected to boost their database and allow them to exchange study resources. The RNA program, which focuses on non-coding RNAs, was recently launched at the Italian Institute of Technology.
The high demand to study on Gene Expression Level through Transcriptomics is expected to help the regional market to offer enough opportunities for the industry players. Low-abundance targets and tiny changes in gene expression, which are crucial for investigating the biological response to stimulation or environmental changes, are difficult to detect with gene microarray methods.
The Germany market dominated the Europe Transcriptomics Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $601.4 million by 2027. The UK market is poised to grow at a CAGR of 6.3% during (2021 - 2027). Additionally, The France market is expected to experience a CAGR of 7.9% during (2021 - 2027).
Based on Technology, the market is segmented into q PCR, Microarrays, and Sequencing Technology. Based on Application, the market is segmented into Drug Discovery, Diagnostics & Disease Profiling, and Others. Based on Component, the market is segmented into Consumables, Instruments, Software, and Services. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Fluidigm Corporation, Promega Corporation, General Electric (GE) Co., Merck & Co., Inc., Thermo Fisher Scientific, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., and Qiagen N.V.
Scope of the Study
Market Segments Covered in the Report:
By Technology
- q PCR
- Microarrays
- Sequencing Technology
By Application
- Drug Discovery
- Diagnostics & Disease Profiling
- Others
By Component
- Consumables
- Instruments
- Software
- Services
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Fluidigm Corporation
- Promega Corporation
- General Electric (GE) Co.
- Merck & Co., Inc.
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- Bio-Rad Laboratories, Inc.
- Agilent Technologies, Inc.
- F. Hoffmann-La Roche Ltd.
- Qiagen N.V.
Unique Offerings from the publisher
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. Europe Transcriptomics Market by Technology
Chapter 5. Europe Transcriptomics Market by Application
Chapter 6. Europe Transcriptomics Market by Component
Chapter 7. Europe Transcriptomics Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Fluidigm Corporation
- Promega Corporation
- General Electric (GE) Co.
- Merck & Co., Inc.
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- Bio-Rad Laboratories, Inc.
- Agilent Technologies, Inc.
- F. Hoffmann-La Roche Ltd.
- Qiagen N.V.
Methodology
LOADING...
